CNTB (Connect Biopharma Holdings) FCF Yield %: -38.44 (As of Jun. 30, 2026)


CNTB Connect Biopharma Holdings Ltd CNTB
7 GF Score
Price $2.38
! 3 Warning Signs
View Full Analysis

What is Connect Biopharma Holdings FCF Yield %?

Connect Biopharma Holdings CNTB +0.42% 7 FCF Yield % is -38.44 as of Jun. 30, 2026. GuruFocus rates CNTB with a GF Score™ of 7/100. The stock has 3 warning signs investors should review. Among 1,415 Biotechnology companies, Connect Biopharma Holdings ranks worse than 79.79% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Connect Biopharma Holdings's Trailing 12-Month Free Cash Flow is $-57.61 Mil, and Market Cap is $149.85 Mil. Therefore, Connect Biopharma Holdings's FCF Yield % for today is -38.44%.

The historical rank and industry rank for Connect Biopharma Holdings's FCF Yield % or its related term are showing as below:

CNTB' s FCF Yield % Range Over the Past 10 Years
Min: -51.43   Med: -39.91   Max: -25.21
Current: -38.44

During the past 7 years, the highest FCF Yield % of Connect Biopharma Holdings was -25.21%. The lowest was -51.43%. And the median was -39.91%.

CNTB's FCF Yield % is ranked worse than
79.79% of 1415 companies
in the Biotechnology industry
Industry Median: -9.49 vs CNTB: -38.44

Connect Biopharma Holdings's FCF Margin % for the quarter that ended in Mar. 2026 was -9,470.41%.

Connect Biopharma Holdings FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Connect Biopharma Holdings FCF Yield % Related Terms

Connect Biopharma Holdings FCF Yield % Historical Data

* Premium members only.

The historical data trend for Connect Biopharma Holdings's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Connect Biopharma Holdings FCF Yield % Chart

Connect Biopharma Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -32.44

Connect Biopharma Holdings Quarterly Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -82.81 -28.31 -38.96

CNTB vs ENLV, SMNR, MENS: FCF Yield % Comparison

For the Biotechnology subindustry, Connect Biopharma Holdings's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Connect Biopharma Holdings FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Connect Biopharma Holdings's FCF Yield % falls into.


CNTB
7GF Score
Connect Biopharma Holdings Ltd CNTB
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Connect Biopharma Holdings FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Connect Biopharma Holdings's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-51.64 / 159.16644
=-32.44%

Connect Biopharma Holdings's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-16.005 * 4 / 164.30544
=-38.96%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -38.44 mean?
Connect Biopharma Holdings (CNTB) has a FCF Yield % of -38.44 as of Jun. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Connect Biopharma Holdings and its competitors. According to the industry distribution chart, Connect Biopharma Holdings ranks #1129 out of 1415 companies in the Biotechnology industry, placing it in the top 79.8%.
Is Connect Biopharma Holdings' FCF Yield % too high?
Connect Biopharma Holdings' current FCF Yield % is -38.44. Based on the distribution chart, Connect Biopharma Holdings ranks #1129 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Connect Biopharma Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Connect Biopharma Holdings' FCF Yield % compare to ENLV and SMNR?
According to the Biotechnology industry distribution chart, Connect Biopharma Holdings ranks #1129 out of 1415 companies for FCF Yield %. This places Connect Biopharma Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Connect Biopharma Holdings and its competitors. Connect Biopharma Holdings's current FCF Yield % is -38.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Connect Biopharma Holdings stock overvalued right now?
Connect Biopharma Holdings (CNTB) has a current FCF Yield % of -38.44. The current FCF Yield % is -38.44. Connect Biopharma Holdings' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Connect Biopharma Holdings (CNTB), the current FCF Yield % is -38.44 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Connect Biopharma Holdings Business Description

Address 3580 Carmel Mountain Road, Suite 200, San Diego, CA, USA, 92130
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
7GF Score

Get the complete analysis for CNTB

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.38
Price